Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2014-12-16 | riluzole | Dr Laurent Vinay (France) | traumatic spinal cord injury |
Granting of the orphan status in the EU |
2014-11-12 | Polyphor (Switzerland) | Ventilator-Associated Bacterial Pneumonia (VABP) caused by Pseudomonas aeruginosa. |
Granting of a Fast Track status | |
2014-11-12 | placental cells | Pluristem Therapeutics (Israel) | muscle trauma, muscle defect, neuropathic pain, peripheral nerve injury, and neurodegenerative diseases |
Granting of a patent |
2014-12-11 | infectious diseases diagnostic platform | Abbott (USA - IL) | Product launch | |
2014-12-10 | Human Papillomavirus 9-valent Vaccine | Merck&Co (USA - NJ) | prevention of cervical, vulvar, vaginal and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58, and for the prevention of genital warts caused by HPV types 6 or 11 |
Granting of a Market Authorisation in the US |
2014-12-11 | enzyme immunoassay | MP Biomedicals (USA - CA) | test for human serum or plasma specimens that have previously tested positive on an FDA-licensed HTLV-I/II blood donor screening test |
Granting of a Market Authorisation in the US |
2014-12-15 | syphilis serological test | Veda Lab (France) Diagnostics Direct (USA - NJ) | syphilis |
Granting of a Market Authorisation in the US |
2016-02-22 | recombinant Factor VIII | Bayer Healthcare (Germany) | hemophilia A |
Granting of a Market Authorisation in the EU |
2014-12-19 | COP allergy vaccine | Anergis (Switzerland) | ragweed allergy |
Granting of a patent |
2014-12-19 | asparaginase Erwinia chrysanthemi | Jazz Pharmaceuticals (Ireland) | patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase |
Granting of a Market Authorisation in the US |
2014-12-04 | immune Globulin Subcutaneous (Human), 20% Liquid | CSL Behring (Australia) | primary and secondary immunodeficiencies |
Granting of a Market Authorisation in the EU |
2016-05-11 | long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP) | CSL Behring (Australia) | hemophilia B |
Granting of a Market Authorisation in the EU |
2015-06-22 | golimumab | Janssen Biologics, a J&J company (USA - NJ) | severe active non-radiographic axial spondyloarthritis (nr-AxSpA) |
Granting of a Market Authorisation in the EU |
2014-11-19 | AXL inhibitor | BergenBio (Norway) | acute myeloid leukaemia |
Granting of the orphan status in the US |
2014-12-10 | ataluren - 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid | PTC Therapeutics (USA - NJ) | mucopolysaccharidosis I (MPS I) | Granting of the orphan status in the US |
2014-11-19 | translocation kit | EMD Millipore (USA - MA) | Product launch | |
2014-11-20 | kits dedicated to the amplification of DNA or RNA species | Sygnis (Germany) | Product launch | |
2017-04-16 | house dust mite (HDM) sublingual allergy immunotherapy tablet (SLIT-tablet) | ALK Abello (Denmark) Merck&Co (USA - NJ) | house dust mite allergic rhinitis and allergic asthma | Granting of a Market Authorisation in the EU |
2015-02-20 | lenalidomide | Celgene (USA - NJ) | treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant patients newly diagnosed with multiple myeloma |
Granting of a Market Authorisation in the EU |
2014-12-01 | 3D Cell Expansion Technology | Pluristem Therapeutics (Israel) | Granting of a patent |
© 2024 Biopharmanalyses - Powered by Samacom+